Loading patent…
AssigneeTargacept, Inc.
InventorsMerouane Bencherif, Nikolai Fedorov, Terry Hauser, Kristen Jordan, Sharon Rae Letchworth, Anatoly Mazurov, Julio A. Munoz, Jason Speake, Daniel Yohannes
Estimating the term…
The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).
A compound (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl-3,5-difluorobenzamide (Formula I) or a pharmaceutically acceptable salt thereof
A compound selected from:
A compound, (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl-3,5-difluorobenzamide or a pharmaceutically acceptable salt thereof containing less than 25% (2R,3R)-, (2S,3S)-, or (2R,3S)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl-3,5-difluorobenzamide, either individually or in combination, by weight.
A compound (2S,3R)-N-2-((3-pyridinyl)methyl-1-azabicyclo[2.2.2]oct-3-yl-3,5-difluorobenzamide (Formula I) or a pharmaceutically acceptable salt thereof
A polymorphic form of a compound (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl-3,5-difluorobenzamide hydrochloride characterized by an x-ray diffraction pattern comprising one or more peaks within ±0.5 degrees 2θ of the following peaks:
A polymorphic form of a compound (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl-3,5-difluorobenzamide hydrochloride characterized by an x-ray powder diffraction pattern that substantially corresponds to FIG. 9.
Dependencies are inferred from the claim text.